Skip to content

TAXUS PHARMACEUTICALS HOLDINGS, INC.: 10-Q filed 2017-05-30

What TAXUS PHARMACEUTICALS HOLDINGS, INC. reported in its quarterly report filed 2017-05-30 (fiscal Q3 2017): 20 published measures, 49 facts as tagged in accession 0001549727-17-000030.

This filing

Form
10-Q (quarterly report)
Filed
2017-05-30
Fiscal period
fiscal Q3 2017
Accession
0001549727-17-000030 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TAXUS PHARMACEUTICALS HOLDINGS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-03-318,959USD
At 2016-06-3063,955USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-03-31-82,056USD
At 2016-06-30-11,961USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-03-315,959USD
At 2016-06-3029,310USD
At 2016-03-3120,852USD
At 2015-06-3013,773USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-32,648USD90
2016-07-01 to 2017-03-31-84,095USD274
2016-01-01 to 2016-03-31-40,819USD91
2015-07-01 to 2016-03-31-138,365USD275

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2016-07-01 to 2017-03-31-37,351USD274
2015-07-01 to 2016-03-31-167,921USD275

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2016-07-01 to 2017-03-315,851USD274
2016-01-01 to 2016-03-3117,260USD91
2015-07-01 to 2016-03-3149,448USD275

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2016-07-01 to 2017-03-3114,000USD274
2015-07-01 to 2016-03-31175,000USD275

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-03-31-670,473USD
At 2016-06-30-586,378USD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-03-315,959USD
At 2016-06-3053,467USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-03-3191,015USD
At 2016-06-3075,916USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2016-06-3024,157USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2016-07-01 to 2017-03-311,462USD274
2016-01-01 to 2016-03-315,870USD91
2015-07-01 to 2016-03-3116,084USD275

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2016-07-01 to 2017-03-314,389USD274
2016-01-01 to 2016-03-3111,390USD91
2015-07-01 to 2016-03-3133,364USD275

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2017-01-01 to 2017-03-3132,648USD90
2016-07-01 to 2017-03-3185,557USD274
2016-01-01 to 2016-03-3146,689USD91
2015-07-01 to 2016-03-31154,449USD275

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-03-3181,500,200shares
At 2016-06-3081,500,200shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2017-03-31587,602USD
At 2016-06-30573,602USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2017-03-312,500USD
At 2016-06-302,500USD

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-16,361USD90
2016-07-01 to 2017-03-31-37,969USD274
2016-01-01 to 2016-03-31-17,144USD91
2015-07-01 to 2016-03-31-58,113USD275

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2015-07-01 to 2016-03-311,111USD275

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2016-07-01 to 2017-03-313,394USD274
2015-07-01 to 2016-03-311,863USD275

Inspect the source

Entity
TAXUS PHARMACEUTICALS HOLDINGS, INC. / CIK 0001622676
Captured
SEC response SHA-256
e3218558022f67a41c23ca87687a0fc1e62f07559dbc817c1e43f7cd112051e5

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001622676.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))